

# Herpes labialis - Pipeline Insight, 2021

<https://marketpublishers.com/r/H0AB803A412EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: H0AB803A412EN

## Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Herpes labialis - Pipeline Insight, 2021," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Herpes labialis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Herpes labialis Understanding

#### Herpes labialis: Overview

Herpes labialis, also known as HSV-1, or oral herpes, is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Symptoms of herpes include painful blisters or ulcers at the site of infection. The prevalence of oral herpes infection is 67% of adults worldwide. Herpes labialis or oral herpes is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Cold sores (herpes labialis) usually go away within 1-2 weeks, but they can be treated with antiviral medications, like acyclovir or topical antiviral creams such as docosanol (Abreva), to reduce pain and shorten healing time.

'Herpes labialis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes labialis pipeline landscape is provided which includes the disease overview and Herpes labialis treatment guidelines. The assessment part of the report embraces, in depth Herpes labialis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes labialis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Herpes labialis R&D. The therapies under development are focused on novel approaches to treat/improve Herpes labialis.

## Herpes labialis Emerging Drugs Chapters

This segment of the Herpes labialis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Herpes labialis Emerging Drugs

### HDIT-101: Heidelberg ImmunoTherapeutics

HDIT-101 is a humanized monoclonal antibody, being developed by Heidelberg ImmunoTherapeutics as a topical application. The drug is in Phase II clinical studies for the treatment of Herpes labialis.

Further product details are provided in the report.....

## Herpes labialis: Therapeutic Assessment

This segment of the report provides insights about the different Herpes labialis drugs

segregated based on following parameters that define the scope of the report, such as:

### Major Players in Herpes labialis

There are approx. 6+ key companies which are developing the therapies for Herpes labialis. The companies which have their Herpes labialis drug candidates in the most advanced stage, i.e. Phase II include, Heidelberg ImmunoTherapeutics.

### Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Herpes labialis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Herpes labialis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Herpes labialis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes labialis drugs.

Herpes labialis Report Insights

Herpes labialis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Herpes labialis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Herpes labialis drugs?

How many Herpes labialis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes labialis?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Herpes labialis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Herpes labialis and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

AiCuris

Heidelberg ImmunoTherapeutics

Ecogene 21

Beech Tree Labs

NanoViricides

Maxwell Biosciences

## Key Products

BOR15001L7

HDIT-101

Pritelivir

BTL-TML

Research programme: Herpes simplex virus nanoparticle therapies

MXB-009

## Contents

- Introduction
- Executive Summary
- Herpes labialis: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Herpes labialis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
  - Comparative Analysis
- Drug name: Company name
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
  - Comparative Analysis
- HDIT-101: Heidelberg ImmunoTherapeutics
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I/II)
  - Comparative Analysis
- Drug name: Company name
  - Product Description
  - Research and Development

Product Development Activities  
Drug profiles in the detailed report  
Preclinical/Discovery Stage Products  
Comparative Analysis  
MXB-009: Maxwell Biosciences  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report  
Inactive Products  
Comparative Analysis  
Herpes labialis Key Companies  
Herpes labialis Key Products  
Herpes labialis- Unmet Needs  
Herpes labialis- Market Drivers and Barriers  
Herpes labialis- Future Perspectives and Conclusion  
Herpes labialis Analyst Views  
Appendix



## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Herpes labialis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Herpes labialis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Herpes labialis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/H0AB803A412EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0AB803A412EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970